NCT04341064 (SHINE) is a Phase 3 clinical trial of SHINE Intervention in Skin Cancer, sponsored by University of Utah.

Who is sponsoring NCT04341064?

NCT04341064 is sponsored by University of Utah.

What drugs are being tested in NCT04341064?

Interventions in NCT04341064: SHINE Intervention.

What condition does NCT04341064 study?

NCT04341064 studies Skin Cancer, Adolescents.

Is NCT04341064 still recruiting?

NCT04341064 is currently completed. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT04341064: SHINE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sun-safe Habits Intervention and Education

Completed Phase 3 Last updated 14 October 2025

What this trial tests

Phase 3 trial testing SHINE Intervention in Skin Cancer in 2,223 participants. Completed in 15 July 2025.

Timeline

14 September 2020

Primary endpoint
15 July 2025

15 July 2025

Quick facts

Lead sponsor	University of Utah
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	2,223
Start date	14 September 2020
Primary completion	15 July 2025
Estimated completion	15 July 2025
Sites	1 location across United States

Drugs / interventions tested

SHINE Intervention

Conditions studied

Skin Cancer — all drugs for Skin Cancer →
Adolescents — all drugs for Adolescents →

Sponsor

University of Utah

Who can join

Adults 11 to 21, any sex, with Skin Cancer or Adolescents. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the efficacy of the Sun-safe Habits Intervention and Education (SHINE) intervention in improving sun protection use and decreasing intentional tanning among high school students. It's anticipated that 30 schools will be randomized into the trial, with approximately half assigned to SHINE and the other half assigned to standard education. After randomization and a baseline assessment, each school will receive two in-class intervention sessions delivered by an interventionist. Follow-up assessments will be completed one month post-intervention, 3-4 months post-intervention, one year post-baseline, and one year post-intervention.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and lessons learned in recruiting participants for school-based disease prevention programs during COVID-19.
Wu YP, Brunsgaard EK, Siniscalchi N, Stump T, et al · · 2024 · cited 1× · PMID 39698166 · DOI 10.1016/j.conctc.2024.101399
Protocol for a cluster-randomized trial of a school-based skin cancer preventive intervention for adolescents.
Wu YP, Stump TK, Hay JL, Buller DB, et al · · 2024 · cited 1× · PMID 38458557 · DOI 10.1016/j.cct.2024.107494

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04341064 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04341064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing